Welcome to our dedicated page for Cyclerion Therapeutics news (Ticker: CYCN), a resource for investors and traders seeking the latest updates and insights on Cyclerion Therapeutics stock.
Cyclerion Therapeutics Inc. (CYCN) is a clinical-stage biopharmaceutical company pioneering treatments for serious and orphan diseases through innovative sGC pharmacology. This page serves as the definitive source for CYCN-related news, providing investors and researchers with timely updates on scientific advancements and corporate developments.
Access curated press releases and analysis covering clinical trial progress, strategic partnerships, and regulatory milestones. Our aggregation includes updates on key programs like sGC stimulator research for conditions including sickle cell disease, neurodegenerative disorders, and cardiovascular therapies.
Discover updates on CYCN's pipeline candidates, licensing agreements, and collaborations within the biopharma sector. Content is organized to help stakeholders track developments in CNS therapies, cardiovascular research, and therapeutic innovation without promotional bias.
Bookmark this page for streamlined access to CYCN's evolving story. Check regularly for verified updates on clinical developments, business strategies, and scientific breakthroughs directly from corporate communications and trusted industry sources.
Cyclerion Therapeutics (CYCN) announced key updates on monetizing its sGC stimulator portfolio. The company renegotiated its praliciguat license agreement with Akebia, securing $1.75 million in upfront and near-term payments, plus potential future milestone payments up to $560 million and tiered sales royalties from mid-single-digits to 20%.
Additionally, CYCN entered an exclusive license option agreement for olinciguat with a CVCO Therapeutics-controlled entity. This follows the May 2023 sale of CNS assets zagociguat and CY3018 to Tisento Therapeutics for $8 million and 10% equity stake.
These agreements represent the final steps in monetizing Cyclerion's historical portfolio, enabling the company to focus on acquiring new CNS assets without near-term dilution.
Cyclerion Therapeutics (Nasdaq: CYCN) has promoted Regina Graul, Ph.D., to Chief Executive Officer, President, and Board member. Since joining in December 2023, Dr. Graul has focused on reducing operating costs and leading a search and evaluation team to assess multiple business development prospects. The company's Board of Directors expressed confidence in her ability to drive growth and success.
Dr. Graul emphasized her commitment to continuing Cyclerion's evolution, highlighting the formation of a top-notch diligence team currently evaluating promising assets. She acknowledged the challenges ahead but expressed confidence in the company's potential to unlock value for patients and shareholders.
Cyclerion Therapeutics (Nasdaq: CYCN) announced that its Independent Board is pursuing a non-binding proposal from a group including its CEO to acquire its zagociguat and CY3018 assets. The Board has entered into exclusive negotiations for this transaction. Additionally, CEO Peter Hecht is set to invest $5 million in equity for Cyclerion, contingent on successful negotiation of documentation. This investment aims to support ongoing operations. All actions remain subject to Board and shareholder approvals, and there is no guarantee of successful completion.
FAQ
What is the current stock price of Cyclerion Therapeutics (CYCN)?
What is the market cap of Cyclerion Therapeutics (CYCN)?
